Encube Ethicals IPO: Rs. 3,000 Crore OFS, Financials and Business Overview
IPO Overview
Encube Ethicals Limited received SEBI observations for its proposed IPO on 4 November 2026. The proposed Rs. 3,000 crore bookbuilding issue consists entirely of an offer for sale, with no fresh capital raised by the company.
The shares are proposed for listing on BSE and NSE. IPO dates, price band, lot size and listing date remain unannounced. SEBI observations permit the offering process to proceed; they are not an investment recommendation.
| Particulars | Details |
|---|---|
| Proposed Issue Size | Rs. 3,000 crore |
| Issue Structure | Entirely Offer for Sale |
| Face Value | Rs. 1 per share |
| IPO Dates | To be announced |
| Price Band and Lot Size | To be announced |
| Listing Exchanges | BSE and NSE |
| Pre-issue Shares | 30,38,84,790 |
| Post-issue Shares | 30,38,84,790, subject to other capital changes |
| DRHP Filing | 3 August 2026 |
| SEBI Observations | 4 November 2026 |
Investor Reservation
| Investor Category | Proposed Allocation |
|---|---|
| Qualified Institutional Buyers | Not more than 50% of the offer |
| Retail Investors | Not less than 35% |
| Non-Institutional Investors | Not less than 15% |
Retail applications are limited to Rs. 2 lakh. Small NII applications exceed Rs. 2 lakh and extend up to Rs. 10 lakh, while large NII applications exceed Rs. 10 lakh. Any employee reservation and eligibility should be confirmed from final offer documents.
Business and Operating Presence
Incorporated in September 1995, Encube Ethicals is a pharmaceutical formulations company specialising in topical and transdermal dosage forms. It serves 50 countries, including the United States, the UK, European markets and India.
The company operates through three business verticals:
- Global Generics: Development and commercialisation of generic pharmaceutical formulations.
- Global CDMO: Contract development and manufacturing services for pharmaceutical customers.
- India Branded Formulations: Marketing branded products through its domestic distribution network.
Its capabilities span research, formulation development, manufacturing, regulatory compliance and commercialisation. Manufacturing facilities and R&D infrastructure support its product pipeline and relationships with international pharmaceutical companies.
As of 31 March 2026, Encube reported 1,695 permanent employees and 982 factory workers.
Key Business Strengths
- Specialisation in topical and transdermal formulations.
- Presence across regulated international markets.
- Integrated generics, CDMO and branded-formulations businesses.
- R&D capabilities supporting product development.
- Established manufacturing infrastructure and customer relationships.
Regulatory compliance, successful product launches and consistent manufacturing quality remain essential to sustaining these strengths.
Financial Performance
Restated consolidated figures, Rs. crore
| Particulars | FY2026 | FY2025 | FY2024 |
|---|---|---|---|
| Total Income | 1,911.80 | 1,369.00 | 1,098.20 |
| EBITDA | 663.30 | 452.10 | 297.60 |
| Profit After Tax | 436.70 | 249.60 | 156.10 |
| Total Assets | 2,792.10 | 2,300.10 | 1,871.80 |
| Net Worth | 1,953.60 | 1,512.80 | 1,258.40 |
| Reserves and Surplus | 1,915.20 | 1,495.20 | 1,243.40 |
| Borrowings | 221.70 | 230.50 | 228.10 |
FY2026 total income increased 39.65%, EBITDA rose 46.72%, and PAT increased 74.96%. Profit growth exceeded income growth, indicating improved overall profitability.
EBITDA as a proportion of total income increased from approximately 33.02% to 34.70%, while PAT margin on total income improved from 18.23% to 22.84%.
Borrowings declined 3.82% to Rs. 221.70 crore, while net worth increased 29.14% to Rs. 1,953.60 crore.
Chanakya Interpretation: Strong earnings growth and relatively modest borrowings support the business profile. Investors should examine product-wise profitability, cash conversion and whether recent margins are sustainable.
Key Performance Indicators and Valuation
| Indicator | Reported FY2026 Reading |
|---|---|
| ROE | 25.65% |
| ROCE | 32.30% |
| Debt/Equity | 0.13 times |
| Return on Net Worth | 25.21% |
| PAT Margin | 23.62% |
| EBITDA Margin | 35.88% |
| NAV per Share | Rs. 64.29 |
| EPS | Rs. 14.37 |
The reported margin KPIs differ from calculations using total income, reflecting a different denominator or definition. Investors should refer to the offer document’s calculation methodology.
P/E and price-to-book valuation await the price band. As the offer is entirely an OFS, it does not itself increase the share count or dilute EPS.
IPO Proceeds and Selling Shareholders
Encube Ethicals will receive no IPO proceeds. The money raised will go to the selling shareholders, after applicable selling expenses.
| Selling Shareholder | Category | Proposed OFS Amount |
|---|---|---|
| Mehul Madhusudan Shah | Promoter | Up to Rs. 2,000 crore |
| Frontier Investment Holdings Pte. Limited | Corporate shareholder | Up to Rs. 1,000 crore |
| Total | Rs. 3,000 crore |
The final number of shares sold will depend on pricing and offer terms.
Mehul Madhusudan Shah is the company’s promoter. The promoter and promoter group hold 80.63% before the IPO, while public shareholders hold 19.37%. Post-offer ownership will depend on the final stake sale.
Chanakya’s Assessment Points
Encube’s financial performance shows strong growth, improving profitability and manageable borrowings. However, the investment decision should await pricing and a detailed examination of:
- Regulatory inspections, observations and remediation requirements.
- US generic-drug pricing and competitive intensity.
- Product, customer and geographical concentration.
- R&D productivity and commercialisation of new products.
- Operating cash flow, working capital and capital expenditure.
- Sustainability of margins and returns on capital.
Chanakya View: Await Pricing. Business growth merits attention, but valuation will determine whether the proposed offer provides an attractive investment opportunity.
Company Address and Contact
Registered office: 803, B Wing, HDIL Kaledonia, Sahar Road, Andheri East, Mumbai, Maharashtra – 400069.
Management interaction route: Company Secretary / Compliance Office
Telephone: +91 22 62288000
Email: compliance.cs@encubeethicals.com
Website: www.encubeethicals.com
Bookrunning lead managers: JM Financial Limited, Axis Capital Limited and Kotak Mahindra Capital Company Limited.
Registrar: MUFG Intime India Private Limited
Telephone: 022-49186000
IPO email: encubeethicals.ipo@in.mpms.mufg.com
Frequently Asked Questions
What is the Encube Ethicals IPO?
It is a proposed Rs. 3,000 crore mainboard IPO consisting entirely of an offer for sale.
When will the IPO open?
The opening and closing dates have not been announced.
What are the price band and lot size?
Both remain unannounced.
Will Encube receive funds from the IPO?
No. Proceeds will go to the selling shareholders.
Where will the shares be listed?
The shares are proposed for listing on BSE and NSE.
AEO / GEO Answer Summary
Encube Ethicals proposes a Rs. 3,000 crore, entirely OFS IPO. The pharmaceutical company specialises in topical and transdermal formulations across generics, CDMO and Indian branded products. FY2026 total income reached Rs. 1,911.80 crore, with PAT of Rs. 436.70 crore. IPO dates, price band and lot size remain awaited. Valuation, regulatory compliance and earnings sustainability are key assessment factors.